vimarsana.com

Latest Breaking News On - Balaxi pharmaceuticals limited - Page 1 : vimarsana.com

Balaxi Pharmaceuticals Reports Continued Solid Growth in Q1 FY23

Hyderabad, Telangana, India Revenue grows 42% in Q1FY23. ​Pharma Revenue in Latin America up 39%. Profit After Tax up 32% YoY. Balaxi Pharmaceuticals Limited (Balaxi), a branded IPR-based pharmaceutical company headquartered in Hyderabad, reported its results for the first quarter of financial year

Balaxi Pharmaceuticals growth remains robust on back of Geographical Expansions

Hyderabad (Telangana) [India], February 1 (ANI/NewsVoir): Balaxi Pharmaceuticals Limited (Balaxi), a branded IPR-based pharmaceutical company headquartered in Hyderabad, reported its results for the third quarter of the financial year 2023 ended December 31, 2022.

Balaxi Pharmaceuticals Limited conducts Groundbreaking Ceremony for its upcoming Rs 85 Cr State-of-the-Art Manufacturing Facility in Hyderabad

Hyderabad (Telangana) [India], December 13 (ANI/NewsVoir): NSE listed Balaxi Pharmaceuticals Limited, a leading IPR branded pharmaceutical company, performed the groundbreaking ceremony of its US-FDA, EU-GMP, WHO-Geneva Compliant Pharmaceutical Formulation Plant at Jadcherla Mandal, Telangana. The company will be investing Rs. 85 crores in the state-of-the-art facility over a period of one year that will enable them to enter European markets as well as enhance margins in current markets. To drive this initiative forward, a leading consultant, Spectrum Pharmatech Consultant Private Limited has been appointed for the smooth and time bound project execution. Spectrum Pharmatech Pvt. Ltd., Mumbai is the Design, Engineering, and Turnkey Execution Consultant for this project. The plant will provide direct and indirect employment to approximately 350+ individuals. This US-FDA, EU-GMP, WHO-Geneva Compliant Pharmaceutical Formulation facility is housed across approximately 1,50,000 square feet,

Balaxi Pharmaceuticals delivers strong growth in Q2 FY23

Hyderabad (Telangana) [India], November 7 (ANI/NewsVoir): Balaxi Pharmaceuticals Limited (Balaxi), a branded IPR-based pharmaceutical company headquartered in Hyderabad, reported its results for the second quarter of FY23. Financial Highlights: Revenue: Robust revenue growth of 23.0 per cent YoY during Q2 FY23 period was led by the Pharmaceuticals business. In this segment, Latin America contributed significantly with 29 per cent growth. Previously launched geographies of Dominican Republic and Guatemala delivered strong expansion whereas Honduras and El Salvador have also initiated business operations and hold immense business potential. In addition, other countries in the region are being lined up for upcoming expansion. In Africa, established operations in Angola resumed growth within the ecosystem of previously registered products, with the Central African Republic that is likely to start contributing from Q4 FY23. EBITDA: During this quarter, EBITDA was higher by 5.2 per cent desp

Balaxi Pharmaceuticals reports Continued Solid Growth in Q1 FY23

Hyderabad (Telangana) [India], August 3 (ANI/NewsVoir): Balaxi Pharmaceuticals Limited (Balaxi), a branded IPR-based pharmaceutical company headquartered in Hyderabad, reported its results for the first quarter of financial year 2023 ended June 30, 2022. Financial Highlights: Quarterly Financial Results for Quarter ending 30.6.22 are not strictly comparable with Quarter ending 30.6.21 due to the consolidation of Balaxi Healthcare LDA Angola (BHA) which became a wholly owned subsidiary of Balaxi Global DMCC with effect from 1st January 2022. Revenue: The strong growth in revenue of 41.9 per cent YoY in Q1FY23 was driven by the pharmaceuticals business, with the LATAM share increasing to 38 per cent. EBITDA: EBITDA of INR 17.03 Cr. was recorded in Q1FY23, registering 35.6 per cent growth YoY, as the Company, despite the cost structures in new geographies incurred ahead of commercial launches in these countries. Profit After Tax: On the back of strong performance of revenue and higher mar

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.